Spasticity in multiple sclerosis and role of glatiramer acetate treatment

Brain and Behavior

Jose Eustasio Meca-Lallana¹  Rocío Hernández-Clares¹ 

[1] Department of Neurology, Multiple Sclerosis Unit, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain

关键词: Clinical effectiveness;    glatiramer acetate;    multiple sclerosis;    muscle spasticity;   

DOI  :  10.1002/brb3.367

来源: Wiley

【 摘 要 】

Abstract

Introduction

Spasticity is one of the most disabling and difficult-to-treat symptoms shown by patients with multiple sclerosis, who often show a suboptimal and unsatisfactory response to classic treatment and new available nonpharmacological alternatives. Due to the progressive nature of this condition, the early management should be essential to improve long-term outcomes.

Methods

We performed a narrative literature review of the contribution of spasticity to the burden of multiple sclerosis and the potential role of classic disease-modifying drugs.

Results

Added to the underlying pathophysiology of spasticity, certain external factors and drugs such as interferon may exacerbate the existing condition, hence their awareness is crucial as part of an effective management of spasticity. Furthermore, the evidence for the effectiveness of glatiramer acetate in preventing spasticity in naïve patients and in those switching from interferon should not be ignored.

Conclusions

This literature review proposes the examination of spasticity and the influence of classic disease-modifying agents on the level of existing condition among the variables to be considered when deciding on therapy for multiple sclerosis in clinical practice.

【 授权许可】

CC BY   
© 2015 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.